ArticlemBio2018
Predicting the Susceptibility of Meningococcal Serogroup B Isolates to Bactericidal Antibodies Elicited by Bivalent rLP2086, a Novel Prophylactic Vaccine.
Open access · goldAbstract read
In one paragraph
Article in mBio, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 33 papers, 1 of them a synthesis that pooled it.
0numbers the graph read from it
0cells of the map it votes in
33citing papers in PubMed, 1 pooled it
6.7field-weighted citation impact, top 2% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
33 citing papers in PubMed, 1 synthesis or guideline pooled it, 66 citations in OpenAlex.
- Meningococcal Vaccination: Recommendations of the Advisory Committee on Immunization Practices, United States, 2020.MMWR. Recommendations and reports : Morbidity and mortality weekly report. Recommendations and reports · 2020Guideline
- Review
- Genomic Typing of Meningococcal Carriage Isolates in an Urban Sexual Health Clinic.Pathogens (Basel, Switzerland) · 2026Article
- Genotypic and phenotypic comparison of Neisseria meningitidis carriage and invasive disease isolates contemporaneously collected in the Netherlands.FEMS microbiology letters · 2026Article
- First use of Trumenba (MenB-fHbp) vaccine to control a nursery outbreak of serogroup B invasive meningococcal disease involving children previously immunised with Bexsero (4CMenB), England, November 2023.Euro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin · 2026Article
- Interlaboratory study to assess precision and reproducibility of the meningococcal antigen surface expression (MEASURE) assay to quantify factor H binding protein expression at the surface of meningococcal serogroup B strains.Diagnostic microbiology and infectious disease · 2025Article
- Methods to evaluate the performance of a multicomponent meningococcal serogroup B vaccine.mSphere · 2025Review
- Fluctuations in serogroup B meningococcal vaccine antigens prior to routine MenB vaccination in France.Communications medicine · 2025Article
- Factor H binding protein (FHbp): An evaluation of genotypic diversity acrossHuman vaccines & immunotherapeutics · 2024Review
- Exploring the sequence diversity and surface expression of Factor H-Binding Protein among invasive serogroup B meningococcal strains from selected European countries.Human vaccines & immunotherapeutics · 2024Article
- Current challenges and improvements in assessing the immunogenicity of bacterial vaccines.Frontiers in microbiology · 2024Review
- Serum bactericidal activity against circulating and reference strains of meningococcal serogroup B in the United States: A review of the strain coverage of meningococcal serogroup B (MenB) vaccines in adolescents and young adults.Human vaccines & immunotherapeutics · 2023Review
- Meningococcal B Immunisation in Adults and Potential Broader Immunisation Strategies: A Narrative Review.Infectious diseases and therapy · 2023Review
- Meningococcal disease in North America: Updates from the Global Meningococcal Initiative.The Journal of infection · 2022Review
- Endogenous complement human serum bactericidal assay (enc-hSBA) for vaccine effectiveness assessments against meningococcal serogroup B.NPJ vaccines · 2021Review
- Broad vaccine protection against Neisseria meningitidis using factor H binding protein.Vaccine · 2020Review
- Recent changes of invasive meningococcal disease in France: arguments to revise the vaccination strategy in view of those of other countries.Human vaccines & immunotherapeutics · 2020Article
- Sex, Age, and Race Effects on Immunogenicity of MenB-FHbp, A Bivalent Meningococcal B Vaccine: Pooled Evaluation of Clinical Trial Data.Infectious diseases and therapy · 2020Article
- US College Students Are at Increased Risk for Serogroup B Meningococcal Disease.Journal of the Pediatric Infectious Diseases Society · 2020Article
- Article
Corrections and comments
- Commented on by
Authors and funding
26 authors at 9 institutions in 7 countries.
Lisa K McNeilPfizer Vaccine Research and Development, Pearl River, New York, USA.
Robert G K DonaldPfizer Vaccine Research and Development, Pearl River, New York, USA.
Alexey GribenkoPfizer Vaccine Research and Development, Pearl River, New York, USA.
Roger FrenchPfizer Vaccine Research and Development, Pearl River, New York, USA.
Nathaniel LambertPfizer Vaccine Research and Development, Pearl River, New York, USA.
Shannon L HarrisPfizer Vaccine Research and Development, Pearl River, New York, USA.
Thomas R JonesPfizer Vaccine Research and Development, Pearl River, New York, USA.
Sheng LiDepartment of Medicine, University of California, San Diego, California, USA.
Gary ZlotnickPfizer Vaccine Research and Development, Pearl River, New York, USA.
Ulrich VogelInstitute for Hygiene and Microbiology, University of Würzburg, Würzburg, Germany.
Heike ClausInstitute for Hygiene and Microbiology, University of Würzburg, Würzburg, Germany.
Raquel AbadReference and Research Laboratory for Vaccine Preventable Bacterial Diseases, Institute of Health Carlos III, Majadahonda, Spain.
Julio A VazquezReference and Research Laboratory for Vaccine Preventable Bacterial Diseases, Institute of Health Carlos III, Majadahonda, Spain.
Ray BorrowPublic Health England, Manchester Royal Infirmary, Manchester, United Kingdom.
Jamie FindlowPublic Health England, Manchester Royal Infirmary, Manchester, United Kingdom.
Muhamed-Kheir TahaInstitut Pasteur, Invasive Bacterial Infections Unit, Paris, France.ORCID 0000-0002-0716-3174
Ala-Eddine DeghmaneInstitut Pasteur, Invasive Bacterial Infections Unit, Paris, France.
Dominique A CaugantDepartment of Bacteriology and Immunology, Norwegian Institute of Public Health, Oslo, Norway.
Paula KrizNational Institute of Public Health, Prague, Czech Republic.
Martin MusilekNational Institute of Public Health, Prague, Czech Republic.
Xin WangMeningitis and Vaccine Preventable Diseases Branch, Centers for Disease Control and Prevention, Atlanta, Georgia, USA.
Jeni VuongMeningitis and Vaccine Preventable Diseases Branch, Centers for Disease Control and Prevention, Atlanta, Georgia, USA.
Leonard W MayerMeningitis and Vaccine Preventable Diseases Branch, Centers for Disease Control and Prevention, Atlanta, Georgia, USA.
Michael W PridePfizer Vaccine Research and Development, Pearl River, New York, USA.
Kathrin U JansenPfizer Vaccine Research and Development, Pearl River, New York, USA.
Annaliesa S AndersonPfizer Vaccine Research and Development, Pearl River, New York, USA Annaliesa.anderson@pfizer.com.
Pfizer (United States) · USCenters for Disease Control and Prevention · USInstituto de Salud Carlos III · ESInstitut Pasteur · FRManchester Royal Infirmary · GBNational Institute of Public Health · CZUniversity of Würzburg · DENorwegian Institute of Public Health · NOUniversity of California San Diego · US
Funding
No grant is acknowledged in the PubMed record.
Abstract
Bivalent rLP2086 (Trumenba), a vaccine for prevention of
Indexed as
Anti-Bacterial AgentsAntibodies, BacterialAntigens, BacterialBacterial ProteinsBlood Bactericidal ActivityFlow CytometryHumansMeningococcal VaccinesMicrobial ViabilityNeisseria meningitidis, Serogroup BAnti-Bacterial AgentsAntibodies, BacterialAntigens, BacterialBacterial Proteinsfactor H-binding protein, Neisseria meningitidisMeningococcal Vaccinesfactor H binding proteinflow cytometrymeningococcal antigen surface expression (MEASURE) assayNeisseria meningitidis serogroup Bvaccine
Identifiers
What OpenQuestion holds
Textmetadata
LicenceCC BY
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.